Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cancer/oncology trials

Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, Zembryki D, Leopold LH (2007) Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC) - A randomized phase II trial. American Journal of Clinical Oncology-Cancer Clinical Trials 30 245-251. [Pg.261]

Fukuoka M, Masuda N, Kudoh S, Negoro S. Irinotecan in small-cell lung cancer—Japanese trials. Oncology (Huntingt) 2000 14(7 Suppl 5) 57-62. [Pg.103]

Brown M, Click HA, Harrell F, Herndon J, McCabe M, Moinpour C et al. Integrating economic analysis into cancer clinical trials the National Cancer Institute-American Society of Clinical Oncology Economics workbook. J Natl Cancer InstMonogr 1998 24 1-28. [Pg.53]

The oncolytic viruses include adenovirus, measles, reovirus, vesicular stomatitis virus (VSV),HSV,poxvirus, and vaccinia. Specific examples include (1) ONYX-015, which is an adenoviral oncolytic virus, administered to patients with liver metastases of colorectal cancer and pancreatic cancer [29], (2) Reolysin, which is an oncolytic reovirus administered to patients with glioma [30], and (3) MV-CEA, which is an oncolytic measles virus expressing carcinoembryonic antigen, administered to patients with ovarian cancer [31]. Some oncolytic viruses are wild type and are apparently not pathogenic in humans, such as the Newcastle disease virus (NDV), which is an RNA avian paramyxovirus. PV701, a naturally attenuated, replication-competent strain of NDV, has been administered to patients with advanced solid tumors [32], The applicability of oncolytic viruses as a therapy for clinical oncology trials is due to their potential selectivity the ability to kill tumor cells but not normal cells. However, the level of attenuation of viral replication in normal cells is limited for most oncolytic vectors. [Pg.727]

Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer pivotal trials. Oncology 2001, 61, 14—21. [Pg.161]

Scharf, O., Golevas, A. D. (2006 Aug 20). Adverse event reporting in publications compared with sponsor database for cancer clinical trials. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 24(24), 3933—3938. [Pg.348]

Ratain Ml. Phase II oncology trials let s be positive. Clin Cancer Res 2005 11 5661-5662. [Pg.684]

Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials there is a better alternative. Clin Cancer Res 2007 13 781-782. [Pg.684]

Abdoler E, Taylor H, Wendler D. The ethics of phase oncology trials. Clin Cancer Res 2008 14 3692-3697. [Pg.684]

SWOG Southwest Oncology Group (an alliance of cancer centers that conducts national clinical trials in cancer)... [Pg.1383]

Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer a gynecologic oncology group study. J Clin Oncol 2003 21 3194-3200. [Pg.1394]

Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004 10 1670-1677. [Pg.1445]

Cauley JA, Martino S, Barrett-Connor E et al. (2004) Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment results of the Continuing Outcomes Relevant to Evista (CORE) trial. Abstract 1018. American Society of Clinical Oncology... [Pg.275]

Purdie D, Cauley J, Disch D et al. (2004) Effect of raloxifene on incidence of invasive breast cancer in postmenopausal women having a history of prior hormone therapy use results of the CORE trial Abstract. European Society of Medical Oncology (ESMO), Vienna... [Pg.278]

Finally, one of fhe most recent and most interesting approvals of a new formulation of paclifaxel was fhe approval of the agent ABl-007 (Abraxane ) (Abraxis Oncology, Schaumburg, IL, U.S.A.) (paclifaxel protein-bound particles for injectable suspension [albumin-bmmd]). It is indicated for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The endpoint for that pivotal trial of Abraxane vs. paclitaxel was a... [Pg.448]

Cooper JS, Guo MD, Herskovie A, et al. Chemoradiotherapy of locally advanced esophageal cancer long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999 281(17) 1623-1627. [Pg.89]

Radiation Therapy Oncology Group RTOG R-0012 Randomized Phase II Trial of Preoperative Combined Modality Chemoradiation for Distal Rectal Cancer... [Pg.101]

Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993 85 704-710. [Pg.142]

Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a Phase I/II trial of hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas Radiation Therapy Oncology Group study 83-02. Cancer 1996 77 1535-1543. [Pg.143]

Fu KK, Phillips TL, Silverberg IJ, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987 5 1410-1418. [Pg.171]

Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998 82 2270-2274. [Pg.171]

Sause WT, Scott C, Taylor S, et al. Phase II trial of combination chemotherapy and irradiation in non-small cell lung cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 1992 15 163-167. [Pg.194]

Clamon G. Herndon J. Cooper R, et al. Radiosensitization with carboplatin forpatients with unresectable stage III non-small-cell lung cancer A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group J Clin Oncol 1999 17 4—11. [Pg.194]

See other pages where Cancer/oncology trials is mentioned: [Pg.199]    [Pg.355]    [Pg.355]    [Pg.96]    [Pg.110]    [Pg.96]    [Pg.75]    [Pg.673]    [Pg.682]    [Pg.1346]    [Pg.273]    [Pg.132]    [Pg.68]    [Pg.412]    [Pg.456]    [Pg.414]    [Pg.71]    [Pg.40]    [Pg.54]    [Pg.78]    [Pg.119]    [Pg.119]    [Pg.122]    [Pg.191]    [Pg.213]    [Pg.262]   
See also in sourсe #XX -- [ Pg.7 , Pg.18 , Pg.45 ]



SEARCH



OncoLogic

Oncology

© 2024 chempedia.info